Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Lung Cancer: early-phase trial registry
7 of 11 indexed Metastatic Lung Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,577 of 28,707 conditions by registered trial count.
11 US clinical trials · 7 currently recruiting · #1,577 of 28,707 conditions by registered trial count
Metastatic Lung Cancer: 11 US clinical trials tracked, 7 recruiting.
Metastatic Lung Cancer is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics), running 2 of these trials.
Enrollment posture brief
Registry condition metastatic-lung-cancer
OPEN 7 | RECR 64% | LATE 1 | EARLY 8 | RANK #1577 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Advanced Melanoma (64% recruiting · 22 trials)
Metastatic Lung Cancer lists 7 open slots (64% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Lung Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Lung Cancer is recruiting above its size-band peers.
7 of 11 indexed trials (63.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Metastatic Lung Cancer research.
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) accounts for 2 of 11 trials (18.2%). 10 distinct sponsors appear on at least one study for this condition label.
-
Typical Metastatic Lung Cancer enrolment sits around 90 participants.
Median target enrolment is 90 among the 11 trials that report a genuine target (sentinel values excluded). 6 of those (54.5%) plan for fewer than 100 participants.
-
Metastatic Lung Cancer research is mostly interventional.
10 interventional and 1 observational studies make up this index (90.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
11 total, page 1 of 1
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Institut de Recherches Internationales Servier
NCT05786924
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
NCT06625775
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
NCT06343402
Exercise as Maintenance Therapy in Advanced Lung Cancer
Indiana University
NCT06513663
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Mirati Therapeutics
NCT05609578
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Obsidian Therapeutics
NCT06060613
Definitive Radiation for High-Risk Spine Metastases
Stony Brook University
NCT06165419
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
Black Diamond Therapeutics
NCT05256290
Irradiation of Large Lung Tumors or Two or More Lung Metastases Simultaneously
The Netherlands Cancer Institute
NCT01543672
Immune Response Under Immunotherapy in Metastatic NSCLC: Sputum, Blood Samples and Microbioata Study
University Hospital, Tours
NCT04804137
Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer
Wake Forest University Health Sciences
NCT03867175
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 2 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Lung Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Lung Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Lung Cancer page
11 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Metastatic Lung Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) sponsors the most Metastatic Lung Cancer trials on record, review their full trial history before evaluating a specific study. See TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Lung Cancer condition card totals 11 registered trials; most-linked intervention stool; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.